Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HER2-positive Metastatic Breast Cancer: early-phase trial registry
4 of 12 indexed HER2-positive Metastatic Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 4 currently recruiting · #1,429 of 28,707 conditions by registered trial count
HER2-positive Metastatic Breast Cancer: 12 US clinical trials tracked, 4 recruiting.
HER2-positive Metastatic Breast Cancer is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition her2-positive-metastatic-breast-cancer
OPEN 4 | RECR 33% | LATE 0 | EARLY 9 | RANK #1429 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
HER2-positive Metastatic Breast Cancer lists 4 open slots (33% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HER2-positive Metastatic Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HER2-positive Metastatic Breast Cancer is recruiting below its size-band peers.
4 of 12 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates HER2-positive Metastatic Breast Cancer research.
Memorial Sloan Kettering Cancer Center accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.
-
Typical HER2-positive Metastatic Breast Cancer enrolment sits around 98 participants.
Median target enrolment is 98 among the 12 trials that report a genuine target (sentinel values excluded). 7 of those (58.3%) plan for fewer than 100 participants.
-
HER2-positive Metastatic Breast Cancer research is mostly interventional.
10 interventional and 2 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT06625775
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
Abramson Cancer Center at Penn Medicine
NCT06551116
PRE-I-SPY Phase I/Ib Oncology Platform Program
QuantumLeap Healthcare Collaborative
NCT05868226
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
University of Miami
NCT05959291
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
Enliven Therapeutics
NCT05650879
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
SystImmune
NCT06714617
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Ambrx
NCT04829604
Testing a New Imaging Agent to Identify Cancer
Memorial Sloan Kettering Cancer Center
NCT04692831
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Criterium
NCT05230810
Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity
Memorial Sloan Kettering Cancer Center
NCT05036252
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
Nancy Lin, MD
NCT03417544
Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Hoffmann-La Roche
NCT02605915
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on HER2-positive Metastatic Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HER2-positive Metastatic Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HER2-positive Metastatic Breast Cancer page
12 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 HER2-positive Metastatic Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most HER2-positive Metastatic Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HER2-positive Metastatic Breast Cancer condition card totals 12 registered trials; most-linked intervention Fam-Trastuzumab Deruxtecan-Nxki; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.